ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II:I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF TH

Abstract

This funding supports INSIGHT Protocol Number: 013, Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC). It is an international multicenter, adaptive, randomized double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of anti-coronavirus hyperimmune intravenous immunoglobulin for the treatment of adult hospitalized patients at the onset of clinical progression of COVID-19.

Key facts

NIH application ID

11199630

Project number

75N91019D00024-P00010-759102000009-1

Recipient

LEIDOS BIOMEDICAL RESEARCH, INC.

Principal Investigator

BETH BASELER

Activity code

N01

Funding institute

NIH

Fiscal year

2024

Award amount

$13,721,004

Award type

—

Project period

2020-04-03 → 2028-07-31